"Avidia's unique discovery engine has the ability to generate products that may provide significant improvements over existing therapeutic modalities, such as antibodies and peptides," said Dr. Lowe of Skyline Ventures. "Based on its successful track record, the company's experienced team can quickly identify and develop viable drug candidates for major diseases and rapidly move them into the clinic."
Part of the funding will also be used for Avidia's research on avimers, single protein chains composed of modular binding domains, thereby allowing the molecule to bind simultaneously to sites on a single protein target and/or multiple protein targets. Avimers represent a new approach to treating multifactorial diseases.
Source: Avidia
Comment Preview